Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Kidney Transplantation 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Alemtuzumab × Genitourinary × 90 days × Clear all
NCT02711202 2026-04-13

Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

Institute for Clinical and Experimental Medicine

Phase NA Completed
20 enrolled 11 charts
Genitourinary

Kidney Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡